Anti-VEGF Anticancer Drugs: Mind the Hypertension

Author(s): Vasiliki Katsi, Zerdes Ioannis*, Manolakou Stavroula, Makris Thomas, Nihoyannopoulos Petros, Tousoulis Dimitris, Kallikazaros Ioannis

Journal Name: Recent Advances in Cardiovascular Drug Discovery (Discontinued)
Formerly Recent Patents on Cardiovascular Drug Discovery

Volume 9 , Issue 2 , 2014


The introduction of therapies that inhibit tumor angiogenesis and particularly target to vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) (VEGF inhibitors/VEGFi) have revolutionized the treatment of various cancer types. Although their clinical benefit can be optimal for cancer-affected patients, the safety of these targeted agents is of special concern especially for longer-term adjuvant or maintenance treatment. Importantly, VEGFi therapy has been significantly associated with hypertension (HTN) as an adverse effect and therefore the control of blood pressure (BP) after the administration of these drugs remains a challenging matter to be faced. The aim of this review is to summarize studies which investigate the association of VEGFi agents with HTN manifestation and the possible risks associated with this complication. Additionally, given that the optimal management of HTN caused by VEGFi remains obscure, this review will focus on prevention strategies including BP monitoring plans and propose potential therapeutic approaches.

Keywords: Anti-VEGF cancer factors, arterial hypertension, axitinib, bevacizumab, cediranib, pazopanib, sorafenib, sunitinib, vandetanib.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Page: [63 - 72]
Pages: 10
DOI: 10.2174/1574890110999150604114127
Price: $58

Article Metrics

PDF: 35